medigraphic.com
Revista Mexicana de Coloproctología Enfermedades del Ano, Recto y Colon

2023, Number 2

<< Back Next >>

Rev Mex Coloproctol 2023; 19 (2)

Application of pressurized intraperitoneal aerosolization chemotherapy (PIPAC) in peritoneal carcinomatosis of colorectal origin

Delgadillo X, Wuthrich P, Torren JJ

Language: Spanish
References: 42
Page: 67-75
PDF size: 384.99 Kb.


ABSTRACT

It is currently well known that an alternative in the modalities of distribution of intraperitoneal solutions for the treatment and control of metastatic lesions, in advanced stages of colorectal cancer is PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) technology. With a simple learning curve, this technology is easily accessible to all budgets, especially bringing promising results in patients, associating good quality of life for all of them, bringing those facts, to make PIPAC procedure a promising method worldwide. This review article exposes "pros and cons" (points of view in favor and points of view against), especially detailed characteristics of PIPAC, its indications and the most suitable devices to carry it out the delivery of drugs.


REFERENCES

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394-424.

  2. Beckert S, Struller F, Grischke EM et al. Chirurgische Therapie der peritonealen Metastasierung in Abhängigkeit von Tumorentität, -stadium und -charakteristik(a) [Surgical Management of Peritoneal Surface Malignancy with Respect to Tumour Type, Tumour Stage and Individual Tumour Biology]. Zentralbl Chir. 2016; 141 (4): 415-420.

  3. Delgadillo X, Londoño E. Nuevos esquemas terapéuticos en estadios avanzados de cáncer de colon. Capítulo No. 70 en: enfermedades de colon, recto y ano: manejo médico-quirúrgico. Ed. Corinter. Veracruz, 2023.

  4. Ceelen WP, Levine E. Intraperitoneal cancer therapy: principles and practice. CRC Press. 2015, 411. doi: 10.1201/b19409.

  5. Delgadillo X. Wuthrich P. PIPAC in colorectal cancer treatment. Delivery of drugs. 2020. Elsevier-Shegokar (Eds.): Vol 2, p 215-226. doi: 10.1016/C2018-0-02119-X.

  6. Reymond MA, Hu B, Garcia A et al. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc. 2000; 14: 51-55.

  7. Solab W, Kerb R, Mürdter T et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014; 21 (2): 553-559.

  8. Moreira A. Delgadillo X, Suarez F, Sarotto L. Pressurized intraperitoneal aerosol chemotherapy (PIPAC). Rev Argent de Cirug. 2020; 112 (3): 311-316. Available in: http://dx.doi.org/10.25132/raac.v112.n3.1443.es

  9. Pocard M, So JBY, Huchon C et al. PIPAC experimental research Group. PIPAC nebulizer: how to test the new devices in the market, expert recommendations. J Visc Surg. 2023; 160 (1): 52-54.

  10. Nowacki M, Alyami M, Villeneuve L et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study. Eur J Surg Oncol. 2018; 44 (7): 991-996.

  11. Alyiami M, Mercier F, Siebert M et al. Unresectable CP treated by PIPAC leading to CRS and HIPEC. Eur J Surg Oncol. 2021; 1: 128-133.

  12. Sadeghi B, Arvieux C, Glehen O et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88 (2): 358-363.

  13. Horvath P, Beckert S, Streuller F, Konigsrainer A, Reymond MA. PIPAC for PM of pancreas and biliary tract cancer. Clin Exp Mets. 2018; 7: 635-640.

  14. Giger-Pabst U, Dentroder C, Falkenstein TA, Ouaissi M, Gotze TO, Tempfer CB. PIPAC for the treatment of malignant mesothelioma. BMC Cancer. 2018; 18 (18): 442.

  15. Tempfer CB, Solass W, Buerkle B, Reymond MA. PIPAC with CIS-DOX for pseudomyxoma peritonei. Gynecol Oncol. 2014; 132 (2): 307-311.

  16. Guel-Klein S, Alberto-Vilchez ME, Ceelen W, Rau B, Brandl A. Is PIPAC a treatment option in upper and lower GI cancer with PM. Visc Med. 2022; 38 (2): 90-98.

  17. Lurvink RJ, Rovers KP, Nienhuijs SW, Creemers GJ, Burger JWA, de Hingj IHJ. PIPAC-OX in patients with colorectal peritoneal metastasis: systematic review. J Gastrointest Oncol. 2021; 12 (Suppl 1): S242-s258.

  18. Mariano G, Pocard M, Eveno C. PIPAC: eight key points for a good practice with video. J Visc Surg. 2019; 156 (2): 169-171.

  19. Sgarbura O, Hübner M, Alyami M et al. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol. 2019; 45 (12): 2386-2391.

  20. Göhler D, Khosrawipour V, Khosrawipour T et al. Technical description of microinjection pump (MIP) and granulometric characterization of the aerosol applied in PIPAC. Surg Endosc. 2017; 31 (4): 1778-1784.

  21. Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Occupational health and safety aspects. Ann Surg Oncol. 2013; 20 (11): 3504-3511.

  22. Alyiami M, Sgarbura O, Khomyakov V et al. Standardizing training for PIPAC. Eur J Surg Oncol. 2020; 46 (12): 2270-2275.

  23. Sgarbura O, Eveno C, Alyiami M et al. Consensus statements for treatment protocols in PIPAC. Pleura Peritoneum J. 2022; 7 (1): 1-7.

  24. Solass W, Herbette A, Schwarz T, Hetzel E, Sun JS, Dutreix M, Reymond MA. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum. Surg Endosc. 2012; 26 (3): 847-852.

  25. Laura M, Lambert A. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. Cancer J Clin. 2015; 65: 283-298.

  26. Girardot-Miglierina A, Clerc D, Alyiami M, Villeneuve L, Sgarbura O, Reymond MA, Hübner M. Consensus statement on safety measures for PIPAC. PAP. 2021; 6 (4): 139-149.

  27. Teixeira-Farinha H, Mattille D, Mantziari S, Demartines N, Hübner M. Early postoperative outcomes of staging laparoscopy for PM with or without PIAC. BMC Surg. 2022; 22 (1): 122.

  28. Graversen M, Pedersen PB, Mortensen MB. Enviromental safety during pressurized intraperitoneal aerosol chemotherapy. PAP. 2017; 1 (4): 203-208.

  29. Demtroder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Color Dis. 2016; 18 (4): 364-371.

  30. Graversen M, Fristrup C, Kristensen TK, Larsen TR, Pfeiffer P, Mortensen MB. Detetctionof free intra peritoneal tumor cells in ascitis from patients with PM before and after PIPAC. J Clin Pathol. 2019; 72 (5): 368-372.

  31. Solab W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS). Pleura and Peritoneum. 2016; 1 (2): 445-454.

  32. Fallah M, Detlefsen S, Ainsworth AP et al. Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum. 2022; 7 (3): 143-148.

  33. Solab W, Sempoux C, Carr NJ et al. Reproductibility of PRGS for the assessment of response to therapy in PM. Histopathol. 2019; 74 (7): 1014-1024.

  34. Delgadillo X, Gaspar T, Wüthrich P. PIPAC Surgical security flow-chart & literature survey. OP ISSPP 2021 2nd Congress. PAP. 2021; 6 (3): eA5-eA6. doi: 10.1515/pp-2021-0141.

  35. Graversen M, Detlefsen S, Pfeiffer P, Lundell L, Mortensen MB. Severe peritoneal sclerosis after repeated PIPAC with Oxaliplatin: report of 2 cases. Clin Exp Metastasis. 2018; 35 (3): 103-108.

  36. Blanco A, Giger-Pabst U, Solab W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013; 20 (7): 2311-2316.

  37. Graversen M, Lundell L, Fristrup C, Pfeiffer P, Mortensen MB. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure. Pleura Peritoneum. 2018; 3 (4): 20180128.

  38. Li Z, Wong LCK, Sultana R et al. A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum. 2022; 7 (2): 39-49.

  39. Delhorme JB, Klipfel A, D'Antonio F et al. Occupational safety of PIPAC in an operating room without laminar airflow. J Visc Surg. 2019; 156 (6): 485-488.

  40. Tidadini F, Abba J, Quesada JL et al. Assessment of postoperative pain after PIPAC in the treatment of peritoneal metastasis. Int J Colorectal Dis. 2022; 37 (7): 1709-1717.

  41. Sugarbaker PH, Van der Speeten K. PIPAC may work but more data is needed. J Gastrointest Oncol 2021; 12 (1): s271-272.

  42. Odendahl K, Solass W, Demtroder C et al. Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol. 2015; 41 (10): 1379-1385.




2020     |     www.medigraphic.com